Table 4.
Comparison among liver transplant recipients, non-alcoholic steatohepatitis and controls regarding endothelial biomarkers
| Variable (pg/mL) | NASH (n = 22) | LTR (n = 44) | Controls (n = 10) | P3 |
| sVCAM-11 | 1692.4 ± 457.4 | 1820.6 ± 443.9 | 1167.2 ± 121.8 | < 0.001 |
| sICAM-11 | 259.7 ± 101 | 230.3 ± 96.3 | 152.9 ± 33.9 | 0.015 |
| MPO1 | 198.3 ± 116.2 | 93.7 ± 60.9 | 409.2 ± 204.9 | < 0.001 |
| Adiponectin1 | 23789.1 ± 12040.4 | 47965.3 ± 33140.8 | 32683.2 ± 25065.4 | 0.008 |
| PAI-11 | 149.2 ± 63.1 | 40.4 ± 28.7 | 132.3 ± 58.4 | < 0.001 |
| SAP1 | 59031.5 ± 17024.2 | 29174.5 ± 20175.2 | 40452.8 ± 18557.44 | < 0.001 |
| SAA2 | 21303 (8723.6-30583.2) | 5390.9 (2567.4-18562.04) | 9008.6 (3230.7-13977.4) | < 0.001 |
| E-selectin2 | 90.03 (69.5-137.1) | 48.5 (36.04-70.9) | 35.7 (28.4-47.04) | < 0.001 |
| MMP-92 | 289.3 (107.6-410.4) | 50.5 (35.2-99.5) | 411.5 (241.2-587.4) | 0.002 |
| HsCRP2 | 1.78 (0.70-3.51) | 0.53 (0.21-1.13) | 0.29 (0.16-0.55) | 0.009 |
Mean ± SD;
Median (25th-75th percentiles); 3Comparisons: sVCAM-1 (LTR = NASH - P = 0.5; LTR > controls - P < 0.001); s-ICAM-1 (LTR = NASH - P = 0.48; LTR > controls - P = 0.05; MPO (LTR < NASH - P = 0.02; LTR < controls - P < 0.001); Adiponectin (LTR > NASH - P = 0.007; LTR = controls - P = 0.27); PAI-1 (LTR < NASH and controls - P < 0.001); SAP (LTR < NASH - P < 0.001; LTR = controls - P = 0.22); SAA (LTR < NASH - P = 0.006; LTR = controls - P = 0.91); E-selectin (LTR < NASH - P = 0.001; LTR > controls - P = 0.04); MMP-9 (LTR < NASH and controls - P < 0.001); CRP (LTR < NASH - P = 0.007; LTR = controls - P = 0.41). sVCAM-1: Soluble vascular cell adhesion molecule-1; sICAM-1: Soluble intracellular cell adhesion molecule-1; PAI-1: Plasminogen activator inhibitor 1; SAP: Serum amyloid P; SAA: Serum amyloid A; MMP-9: Matrix metallopeptidase 9; HsCRP: High-sensitivity C-reactive protein; LTR: Liver transplant recipients; NASH: Non-alcoholic steatohepatitis.